MedPath

Effect of Tropicamide 0.5% vs Tropicamide 1% on Intraocular Pressure of Diabetic Patients

Phase 3
Completed
Conditions
Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus
Interventions
Registration Number
NCT04932213
Lead Sponsor
Semnan University of Medical Sciences
Brief Summary

The aim of this study is to compare the effect of tropicamide 0.5% and tropicamide 1% on intraocular pressure and anterior chamber parameters in patients with Diabetes Mellitus.

Detailed Description

Patients with diabetes type 1 and type 2 older than 21 years of age, in the specialized clinic of Kowsar Hospital (Semnan University of Medical Sciences) are examined. Eligible individuals enter the study and are randomly assigned to group 1 or group 2. In each group, visual acuity measurement, slit lamp biomicroscopy and fundus examination are performed. Intraocular pressure is measured with Goldmann applanation tonometer. pupil size, refraction and keratometry are measured with two different autorefractokeratometers. keratometry, pupil size and other anterior chamber parameters are also evaluated by Oculus Pentacam imaging. Then, the patients receive tropicamide 0.5% drops in group 1 and tropicamide 1% drops in group 2. 30 minutes later, all previous measurements are repeated. Patients and the ophthalmologist and the data analyzer are unaware of the drug type.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
98
Inclusion Criteria
  • Patients with Diabetes Mellitus type 1 and 2
Exclusion Criteria
  • Proliferative diabetic retinopathy
  • History of cataract surgery
  • severe nuclear and cortical cataract
  • Glaucoma
  • Intraocular pressure (IOP) greater than 21 mmHg
  • Familial history of glaucoma
  • Narrow angle (Van Herick 1, 2)
  • Cup to disc ratio greater than 0.5
  • Pregnancy
  • Pterygium
  • Corneal ectasia
  • History of keratorefractive surgery
  • Corneal dystrophy
  • Iris disorders
  • Anisocoria
  • Iris neovascularization
  • Use of miotics or mydriatics

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Tropicamide 0.5%Tropicamide OphthalmicThis group receives tropicamide 0.5% (one drop every 5 minutes for 2 times) drops.
Tropicamide 1%Tropicamide OphthalmicThis group receives tropicamide 1% (one drop every 5 minutes for 2 times) drops.
Primary Outcome Measures
NameTimeMethod
Change from baseline in Intraocular pressure (IOP)Before intervention, 30 minutes after intervention

The intraocular pressure is measured by Goldmann applanation tonometry

Change from baseline in pupillary diameterBefore intervention, 30 minutes after intervention

The diameter of the participants' pupil is measured by Scheimpflug camera (Oculus Pentacam); Autorefractokeratometer (TOMEY RC-5000 and Topcon KR-1)

Secondary Outcome Measures
NameTimeMethod
Change from baseline in anterior chamber angle (ACA)Before intervention, 30 minutes after intervention

The ACA is measured by Scheimpflug camera (Oculus Pentacam)

Change from baseline in central corneal thickness (CCT)Before intervention, 30 minutes after intervention

The CCT is measured by Scheimpflug camera (Oculus Pentacam)

Change from baseline in KeratometryBefore intervention, 30 minutes after intervention

The keratometry is obtained by Scheimpflug camera (Oculus Pentacam); Autorefractokeratometer (TOMEY RC-5000 and Topcon KR-1)

Change from baseline in anterior chamber depth (ACD)Before intervention, 30 minutes after intervention

The ACD is measured by Scheimpflug camera (Oculus Pentacam)

Change from baseline in anterior chamber volume (ACV)Before intervention, 30 minutes after intervention

The ACV is measured by Scheimpflug camera (Oculus Pentacam)

Trial Locations

Locations (1)

Kowsar Semnan Research and Medical Training Center

🇮🇷

Semnan, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath